Cipla ​has received 8 inspectional observations in Form 483

Cipla has received 8 inspectional observations in Form 483 from USFDA after cGMP inspection at Pithampur plant.

United States Food and Drug Administration (USFDA) conducted a current Good Manufacturing Practices (cGMP) inspection at Pithampur manufacturing facility of Cipla from 6th – 17th February, 2023.

Cipla said that it will work closely with the USFDA and is committed to address these comprehensively within stipulated time.